Security
Vogenx Inc Common Stock · VOGX
VOGXNASDAQCommon stockCurrentCIK 1903784Updated Oct 12, 2026
VOGX price & chart
Loading TradingView…
NASDAQ:VOGX on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
4 filing
4 filing
4 filing
4 filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
10-Q filing
Other Events
Items 8.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
S-8 filing
Offerings
Registration 333-297487
- Gross proceeds
- 81250000.0
- Net proceeds
- 75562500.0
- Deal price
- 13.0
- Shares
- 6250000
- Offering price
- $13.00
- Ticker
- VOGX
Underwriters: Jones
Filing attachments
vogenxex99-1.htm · 8-K · 2026-10-09
Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer Appointment strengthens corporate strategy, business development and commercial readiness as the Company advances mizagliflozin following its August 2026 initial public offering RA…
Read attachment ↗vogenxex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Ken Toombs to Board of Directors Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company scales operations following its August 2026 initial public offering RALEIGH, N.C., September 22, 2026 - Vogenx, Inc. (Na…
Read attachment ↗vogenxex4-3.htm · S-1/A · 2026-07-29
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗vogenxex4-2.htm · S-1 · 2026-07-15
Exhibit 4.2 THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN EXEMPTION FROM REGISTRATION AVAILABLE SO THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AM…
Read attachment ↗vogenxex4-3.htm · S-1 · 2026-07-15
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗